AmerisourceBergen to Launch Digital Therapeutics Platform to Facilitate Access to Innovative Products

Conshohocken, Pennsylvania (USA) (27. Juli) – Da die Pipeline an digitalen Therapeutika (DTx) weiter wächst, gab AmerisourceBergen heute Pläne für die Einführung von DTx Connect bekannt, einer vollständig integrierten Plattform für Bestellung, Abgabe und Fulfillment, die darauf abzielt, Patienten den Zugang zu ärztlich verordneten digitalen Therapeutika und Diagnostika zu erleichtern. Die Plattform, die sich nahtlos in elektronische Patientenakten (EMR) integrieren lässt, ermöglicht es Ärzten, über ihren E-Verschreibungs-Workflow einfach auf verschreibungspflichtige und nicht verschreibungspflichtige DTx zuzugreifen und diese zu bestellen und anschließend die Patientenzufriedenheit zu überwachen.

DTx ist eine schnell wachsende Kategorie innerhalb der digitalen Gesundheit und liefert klinische Interventionen direkt an Patienten über Software, um ein breites Spektrum von Krankheiten und Störungen, einschließlich Verhaltensstörungen und Diabetes, zu behandeln, zu verwalten oder zu verhindern. Die Produkte, die gelegentlich verschreibungspflichtig sind, können als eigenständige Therapien oder in Kombination mit anderen Behandlungen oder Geräten verwendet werden. Digitale Therapeutika unterscheiden sich von anderen digitalen Gesundheitsinstrumenten zum Teil dadurch, dass sie von den Aufsichtsbehörden zugelassen oder zertifiziert werden müssen, um die Behauptungen über Risiko, Wirksamkeit und Verwendungszweck zu untermauern. Es wird prognostiziert, dass der Markt in den Vereinigten Staaten von 2022 bis 2030 mit einer durchschnittlichen jährlichen Wachstumsrate von fast 25 % wachsen wird.

Mehrere digitale Gesundheitsunternehmen planen, die Plattform zu testen, darunter Mahana Therapeutics, ein führender Entwickler von verschreibungspflichtigen digitalen Therapeutika, die Patienten mit chronischen Erkrankungen unterstützen sollen, und Videra Health, eine KI-gestützte Videobewertungs- und Fernüberwachungsplattform für Patienten.

“While digital therapeutics and diagnostics offer tremendous potential, addressing challenges across the provider workstream and patient journey remain critical to unlocking the value these products have to offer,” said Jason Dinger, SVP of Strategy and Innovation at AmerisourceBergen. “Given our role in the supply chain and our portfolio of commercialization services, we are uniquely positioned to build a solution that aims to address unmet needs and helps patients start and stay on physician-ordered products. DTx Connect, in addition to AmerisourceBergen’s patient support and market access consulting services, enables us to deliver enhanced support across the product lifecycle, helping to advance accessibility.”

DTx Connect, which is EMR- and brand-agnostic, provides a real-time, secure digital connection between developers and physicians via the EMR. The platform is powered through a collaboration with patient engagement technology company Twistle. Key features include:

• E-prescribing through EMR: Physicians can search for digital therapeutics and diagnostic tools via a digital catalog and then order the products within their e-prescribing workflow.
• Efficient dispense and fulfillment: After a physician orders a product, DTx Connect delivers a welcome message on behalf of the care team via text or within the patient portal. Patients also receive an electronic link which enables them to download the prescription or non-prescription product and access educational materials.
• Patient support services: Patient services—delivered via text, a digital companion app, and phone calls with clinical teams—aim to simplify the adoption and onboarding process, keep patients engaged throughout the treatment journey and monitor and manage adherence.
• Patient Status Alerts: DTx Connect provides physicians with patient status alerts, including notifications for patient fulfillment. The increased visibility throughout the patient journey enables physicians to make more informed engagement and care plan decisions in support of the prescribed therapy regimen.

“AmerisourceBergen has spent decades ensuring that patients have timely access to healthcare products. Their experience will bring a unique perspective to our community, particularly as they launch DTx Connect," said Andy Molnar, CEO of the Digital Therapeutics Alliance (DTA), a global nonprofit trade association of industry leaders and stakeholders engaged in the evidence-driven advancement of digital therapeutics. AmerisourceBergen is a member of DTA. “Getting digital therapeutics into the hands of more people who need them is a primary focus of DTA's global efforts and platforms like DTx Connect will help advance accessibility of high quality, evidence-based DTx products."

The launch of DTx Connect bolsters the support AmerisourceBergen offers to DTx developers throughout the commercialization journey. In addition to the capabilities available through DTx Connect, AmerisourceBergen can deliver services to support DTx developers’ strategic planning and launch activities, including market access consulting, real-world evidence planning and engaging healthcare decision makers via AB’s FormularyDecisions platform. For more information on DTx Connect, please visit: https://www.amerisourcebergen.com/manufacturer-solutions/digital-therapeutics

###

About AmerisourceBergen

AmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the development and delivery of pharmaceuticals and healthcare products. As a leading global healthcare company, with a foundation in pharmaceutical distribution and solutions for manufacturers, pharmacies and providers, we create unparalleled access, efficiency and reliability for human and animal health. Our 42,000 global team members power our purpose: We are united in our responsibility to create healthier futures. AmerisourceBergen is ranked #10 on the Fortune 500 with more than $200 billion in annual revenue. Learn more at www.amerisourcebergen.com.